Shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) have received a consensus rating of “Buy” from the twenty-one analysts that are presently covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and seventeen have assigned a buy recommendation to the company. The average 1 year price objective among brokerages that have issued ratings on the stock in the last year is $180.77.

JAZZ has been the subject of a number of recent analyst reports. TheStreet raised shares of Jazz Pharmaceuticals PLC from a “c+” rating to a “b-” rating in a research note on Tuesday, March 28th. Cantor Fitzgerald set a $187.00 price target on shares of Jazz Pharmaceuticals PLC and gave the stock a “buy” rating in a research note on Wednesday, March 1st. Leerink Swann set a $170.00 price target on shares of Jazz Pharmaceuticals PLC and gave the stock a “buy” rating in a research note on Wednesday, March 1st. Stifel Nicolaus dropped their price target on shares of Jazz Pharmaceuticals PLC from $200.00 to $190.00 and set a “buy” rating for the company in a research note on Wednesday, March 1st. Finally, Mizuho reaffirmed a “buy” rating and set a $152.00 price target on shares of Jazz Pharmaceuticals PLC in a research note on Wednesday, March 1st.

In other news, EVP Suzanne Sawochka Hooper sold 2,500 shares of the business’s stock in a transaction dated Thursday, April 27th. The shares were sold at an average price of $160.00, for a total value of $400,000.00. Following the completion of the sale, the executive vice president now owns 39,649 shares in the company, valued at approximately $6,343,840. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, SVP Karen J. Wilson sold 11,458 shares of the business’s stock in a transaction dated Monday, April 10th. The shares were sold at an average price of $152.24, for a total transaction of $1,744,365.92. Following the completion of the sale, the senior vice president now owns 27,158 shares of the company’s stock, valued at approximately $4,134,533.92. The disclosure for this sale can be found here. In the last 90 days, insiders sold 54,333 shares of company stock valued at $8,345,824. Company insiders own 3.90% of the company’s stock.

Hedge funds and other institutional investors have recently bought and sold shares of the company. Russell Investments Group Ltd. purchased a new position in Jazz Pharmaceuticals PLC during the fourth quarter valued at approximately $3,043,000. Raymond James Financial Services Advisors Inc. purchased a new position in Jazz Pharmaceuticals PLC during the fourth quarter valued at approximately $295,000. Dimensional Fund Advisors LP raised its position in Jazz Pharmaceuticals PLC by 0.3% in the fourth quarter. Dimensional Fund Advisors LP now owns 147,511 shares of the specialty pharmaceutical company’s stock valued at $16,082,000 after buying an additional 408 shares during the period. Tredje AP fonden raised its position in Jazz Pharmaceuticals PLC by 55.1% in the fourth quarter. Tredje AP fonden now owns 2,513 shares of the specialty pharmaceutical company’s stock valued at $274,000 after buying an additional 893 shares during the period. Finally, Aviva PLC raised its position in Jazz Pharmaceuticals PLC by 5.5% in the fourth quarter. Aviva PLC now owns 35,839 shares of the specialty pharmaceutical company’s stock valued at $3,908,000 after buying an additional 1,871 shares during the period. Hedge funds and other institutional investors own 88.96% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Jazz Pharmaceuticals PLC (JAZZ) Given Average Recommendation of “Buy” by Brokerages” was first posted by American Banking News and is the property of of American Banking News. If you are reading this article on another website, it was stolen and reposted in violation of U.S. and international copyright & trademark legislation. The legal version of this article can be accessed at https://www.americanbankingnews.com/2017/06/23/jazz-pharmaceuticals-plc-jazz-given-average-recommendation-of-buy-by-brokerages.html.

Shares of Jazz Pharmaceuticals PLC (JAZZ) traded down 0.43% during trading on Friday, hitting $158.80. 739,399 shares of the stock traded hands. Jazz Pharmaceuticals PLC has a 12 month low of $95.80 and a 12 month high of $163.75. The firm’s 50-day moving average price is $152.09 and its 200-day moving average price is $135.76. The stock has a market cap of $9.53 billion, a PE ratio of 24.00 and a beta of 1.10.

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) last released its quarterly earnings results on Tuesday, May 9th. The specialty pharmaceutical company reported $1.41 EPS for the quarter, missing analysts’ consensus estimates of $1.42 by $0.01. Jazz Pharmaceuticals PLC had a return on equity of 24.65% and a net margin of 26.28%. The firm had revenue of $376.10 million for the quarter, compared to analysts’ expectations of $376.58 million. During the same period in the prior year, the firm posted $2.26 earnings per share. Jazz Pharmaceuticals PLC’s revenue for the quarter was up 11.9% on a year-over-year basis. Analysts anticipate that Jazz Pharmaceuticals PLC will post $11.00 EPS for the current year.

About Jazz Pharmaceuticals PLC

Jazz Pharmaceuticals, Inc is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry. As of December 31, 2009, the Company markets two products: Xyrem (sodium oxybate) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; and Luvox CR (fluvoxamine maleate) for the treatment of both obsessive compulsive disorder and social anxiety disorder.

Receive News & Ratings for Jazz Pharmaceuticals PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals PLC and related companies with MarketBeat.com's FREE daily email newsletter.